Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib (Q39683930)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 21 November 2011

Language	Label	Description	Also known as
English	Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib	scientific article published on 21 November 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

circulatory system

1 reference

based on heuristic

inferred from title

1

object named as

Magnus Bäck

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

3

object named as

Erik Ingelsson

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Li Yin

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

publication date

21 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

European Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1928-1933

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Inflammation as a risk factor for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

COX-2 and the kidney

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Targeted deletions of cyclooxygenase-2 and atherogenesis in mice.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Pericardial prostaglandin biosynthesis prevents the increased incidence of reperfusion-induced ventricular fibrillation produced by efferent sympathetic stimulation in dogs

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Prostaglandins in the pericardial fluid modulate neural regulation of cardiac electrophysiological properties

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

The effects of prostaglandins E2, F2 alpha, prostacyclin, flurbiprofen and aspirin on arrhythmias resulting from coronary artery ligation in anaesthetized rats

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countries

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR421

21 January 2018

Identifiers

10.1093/EURHEARTJ/EHR421

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39683930&oldid=2111809460"